pSivida Corp. (NASDAQ:PSDV) – Investment analysts at B. Riley lifted their Q3 2018 earnings per share (EPS) estimates for shares of pSivida in a research report issued to clients and investors on Thursday. B. Riley analyst A. D’silva now expects that the company will post earnings per share of ($0.14) for the quarter, up from their previous estimate of ($0.15). B. Riley currently has a “Buy” rating and a $5.00 target price on the stock. B. Riley also issued estimates for pSivida’s Q4 2018 earnings at ($0.12) EPS and FY2018 earnings at ($0.54) EPS.
pSivida (NASDAQ:PSDV) last posted its quarterly earnings results on Wednesday, February 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. The business had revenue of $0.93 million during the quarter, compared to analysts’ expectations of $0.48 million. pSivida had a negative net margin of 882.37% and a negative return on equity of 198.23%.
pSivida (NASDAQ:PSDV) opened at $1.04 on Monday. pSivida has a fifty-two week low of $0.93 and a fifty-two week high of $2.45. The stock has a market cap of $47.07, a price-to-earnings ratio of -1.76 and a beta of 1.26.
An institutional investor recently bought a new position in pSivida stock. OxFORD Asset Management LLP purchased a new stake in pSivida Corp. (NASDAQ:PSDV) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned 0.18% of pSivida as of its most recent filing with the SEC. 9.70% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “pSivida Corp. (PSDV) to Post Q3 2018 Earnings of ($0.14) Per Share, B. Riley Forecasts” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/psivida-corp-psdv-to-post-q3-2018-earnings-of-0-14-per-share-b-riley-forecasts.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.